The Negative Regulation of MiR-149-5p in Melanoma Cell Survival and Apoptosis by Targeting LRIG2

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2017 Oct 6

PMID 28979706

Citations 18

Authors

Wenqi Chen

Jinhai Zhang

Huijuan Xu

Jie Dai

Xiaorong Zhang

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are key regulators of diverse biological processes in tumor progression including melanoma. LRIG2 is reported as an oncogene in cancer, however, little is known regarding the molecular and functions of LRIG2 in melanoma. In this study, we reported that LRIG2 expression was higher in melanoma tissues and cell lines and was regulated by miR-149-5p. Furthermore, a luciferase reporter assay and rescue experiment indicated that miR-149-5p directly targeted LRIG2 by binding its 3'UTR. The overexpression of miR-149-5p significantly suppressed melanoma cell proliferation, colony formation, and promoted cell apoptosis. These results suggest that miR-149-5p acts as a suppressing molecule and may be a good method for melanoma therapy.

Citing Articles

Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.

Afsar S, Syed R, Khojali W, Masood N, Osman M, Jyothi J Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):297-317.

PMID: 39167168 DOI: 10.1007/s00210-024-03366-3.

Asymmetric and parallel subgenome selection co-shape common carp domestication.

Wang M, Li X, Wang C, Zou M, Yang J, Li X BMC Biol. 2024; 22(1):4.

PMID: 38166816 PMC: 10762839. DOI: 10.1186/s12915-023-01806-9.

Effect of miR-149-5p on intramuscular fat deposition in pigs based on metabolomics and transcriptomics.

Liu Y, Wei Y, Dou Y, Li C, Song C, Zhang Z BMC Genomics. 2023; 24(1):293.

PMID: 37259030 PMC: 10230699. DOI: 10.1186/s12864-023-09382-6.

LRIG2 regulates cell proliferation, migration and apoptosis of osteosarcoma.

Li Z, Liao W, Sun B, Luo Z, Zhong N, Wu J BMC Cancer. 2022; 22(1):1029.

PMID: 36183058 PMC: 9526349. DOI: 10.1186/s12885-022-10123-3.

Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin.

Januszyk S, Mieszczanski P, Lurka H, Sagan D, Boron D, Grabarek B Biomedicines. 2022; 10(5).

PMID: 35625926 PMC: 9138494. DOI: 10.3390/biomedicines10051190.

References

Simion C, Cedano-Prieto M, Sweeney C . The LRIG family: enigmatic regulators of growth factor receptor signaling. Endocr Relat Cancer. 2014; 21(6):R431-43. PMC: 4182143. DOI: 10.1530/ERC-14-0179. View

Varamo C, Occelli M, Vivenza D, Merlano M, Lo Nigro C . MicroRNAs role as potential biomarkers and key regulators in melanoma. Genes Chromosomes Cancer. 2016; 56(1):3-10. DOI: 10.1002/gcc.22402. View

Guo D, Yang H, Guo Y, Xiao Q, Mao F, Tan Y . LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor. J Neurol Sci. 2015; 350(1-2):61-8. DOI: 10.1016/j.jns.2015.02.015. View

Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R . Characterization and tissue-specific expression of human LRIG2. Gene. 2004; 332:35-43. DOI: 10.1016/j.gene.2004.02.002. View

Su B, Zhou S, Gan C, Zhang X . MiR-330-5p regulates tyrosinase and PDIA3 expression and suppresses cell proliferation and invasion in cutaneous malignant melanoma. J Surg Res. 2016; 203(2):434-40. DOI: 10.1016/j.jss.2016.03.021. View

Xiao Q, Tan Y, Guo Y, Yang H, Mao F, Xie R . Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. PLoS One. 2014; 9(10):e111419. PMC: 4213030. DOI: 10.1371/journal.pone.0111419. View

Maadi H, Moshtaghian A, Taha M, Mowla S, Kazeroonian A, Haass N . Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. Int J Biochem Cell Biol. 2016; 81(Pt A):121-132. DOI: 10.1016/j.biocel.2016.11.004. View

Wang G, Wu J, Song H . LRIG2 expression and prognosis in non-small cell lung cancer. Oncol Lett. 2014; 8(2):667-672. PMC: 4081377. DOI: 10.3892/ol.2014.2157. View

Sun X, Li J, Sun Y, Zhang Y, Dong L, Shen C . miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget. 2016; 7(33):53558-53570. PMC: 5288205. DOI: 10.18632/oncotarget.10669. View

10.

Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H . Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology. 2008; 29(3):242-7. DOI: 10.1111/j.1440-1789.2008.00970.x. View

11.

Felicetti F, De Feo A, Coscia C, Puglisi R, Pedini F, Pasquini L . Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J Transl Med. 2016; 14:56. PMC: 4765208. DOI: 10.1186/s12967-016-0811-2. View

12.

Andrews M, Cursons J, Hurley D, Anaka M, Cebon J, Behren A . Systems analysis identifies miR-29b regulation of invasiveness in melanoma. Mol Cancer. 2016; 15(1):72. PMC: 5112703. DOI: 10.1186/s12943-016-0554-y. View

13.

Wozniak M, Mielczarek A, Czyz M . miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential. Curr Med Chem. 2016; 23(28):3136-3153. DOI: 10.2174/1389557516666160831164544. View

14.

Wang Y, Poulin E, Coffey R . LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer. 2013; 108(9):1765-70. PMC: 3658528. DOI: 10.1038/bjc.2013.138. View

15.

Hedman H, Henriksson R . LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?. Eur J Cancer. 2007; 43(4):676-82. DOI: 10.1016/j.ejca.2006.10.021. View

16.

Grieco F, Sebastiani G, Juan-Mateu J, Villate O, Marroqui L, Ladriere L . MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells. Diabetes. 2016; 66(1):100-112. PMC: 5204315. DOI: 10.2337/db16-0592. View

17.

Lindquist D, Kvarnbrink S, Henriksson R, Hedman H . LRIG and cancer prognosis. Acta Oncol. 2014; 53(9):1135-42. PMC: 4438349. DOI: 10.3109/0284186X.2014.953258. View

18.

Hedman H, Lindstrom A, Tot T, Stendahl U, Henriksson R, Hellberg D . LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol. 2010; 49(6):812-5. DOI: 10.3109/0284186X.2010.492789. View

19.

Mazar J, Qi F, Lee B, Marchica J, Govindarajan S, Shelley J . MicroRNA 211 Functions as a Metabolic Switch in Human Melanoma Cells. Mol Cell Biol. 2016; 36(7):1090-108. PMC: 4800793. DOI: 10.1128/MCB.00762-15. View

20.

Fattore L, Costantini S, Malpicci D, Ruggiero C, Ascierto P, Croce C . MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017; 8(13):22262-22278. PMC: 5400662. DOI: 10.18632/oncotarget.14763. View